×
DURECT Goodwill and Intangible Assets 2010-2024 | DRRX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
DURECT goodwill and intangible assets from 2010 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
View More
DURECT Goodwill and Intangible Assets 2010-2024 | DRRX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
DURECT goodwill and intangible assets from 2010 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$74.8B
Chugai Pharmaceutical (CHGCY)
$70.2B
Takeda Pharmaceutical (TAK)
$41.1B
Sandoz Group AG (SDZNY)
$19.6B
Merck (MKKGY)
$18.8B
Astellas Pharma (ALPMY)
$17.3B
United Therapeutics (UTHR)
$16B
Neurocrine Biosciences (NBIX)
$14.5B
Summit Therapeutics (SMMT)
$14B
Shionogi (SGIOY)
$12.1B
Orion OYJ (ORINY)
$7.2B
Stevanato Group S.p.A (STVN)
$6.9B
Madrigal Pharmaceuticals (MDGL)
$6.4B
Corcept Therapeutics (CORT)
$5.8B
Hikma Pharmaceuticals Plc (HKMPF)
$5.5B
Grifols, S.A (GRFS)
$5B
Ionis Pharmaceuticals (IONS)
$5B
Crinetics Pharmaceuticals (CRNX)
$3.5B
Catalyst Pharmaceuticals (CPRX)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Recursion Pharmaceuticals (RXRX)
$2.6B
NewAmsterdam Pharma (NAMS)
$2.2B
Soleno Therapeutics (SLNO)
$2B
Centessa Pharmaceuticals (CNTA)
$2B
Hypermarcas (HYPMY)
$1.9B
Indivior (INDV)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.5B
Evotec AG (EVO)
$1.5B
Dyne Therapeutics (DYN)
$1.4B
Xencor (XNCR)
$1.3B